ES2107414T3 - Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis. - Google Patents

Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.

Info

Publication number
ES2107414T3
ES2107414T3 ES90104936T ES90104936T ES2107414T3 ES 2107414 T3 ES2107414 T3 ES 2107414T3 ES 90104936 T ES90104936 T ES 90104936T ES 90104936 T ES90104936 T ES 90104936T ES 2107414 T3 ES2107414 T3 ES 2107414T3
Authority
ES
Spain
Prior art keywords
erythropoyesis
stimulation
beta
human interferon
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90104936T
Other languages
English (en)
Inventor
Rita Michalevicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Interpharm Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Interpharm Laboratories Ltd filed Critical Ramot at Tel Aviv University Ltd
Application granted granted Critical
Publication of ES2107414T3 publication Critical patent/ES2107414T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE UTILIZA INTERFERON-BETA, PREFERIBLEMENTE EN DOSIS BAJAS, PARA LA ESTIMULACION DE LA ERITROPOYESIS EN DESORDENES CARACTERIZADOS PORQUE LAS CELULAS SANGUINEAS DEL PROGENITOR NO MADURAN COMO CELULAS ROJAS.
ES90104936T 1989-03-19 1990-03-15 Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis. Expired - Lifetime ES2107414T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL89662A IL89662A (en) 1989-03-19 1989-03-19 Pharmaceutical compositions comprising interferon-beta

Publications (1)

Publication Number Publication Date
ES2107414T3 true ES2107414T3 (es) 1997-12-01

Family

ID=11059803

Family Applications (2)

Application Number Title Priority Date Filing Date
ES90104936T Expired - Lifetime ES2107414T3 (es) 1989-03-19 1990-03-15 Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ES94112221T Expired - Lifetime ES2198409T3 (es) 1989-03-19 1990-03-15 Utilizacion del interferon-beta humano para la preparacion de composiciones farmaceuticas para el tratamiento de la leucemia mieloide cronica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94112221T Expired - Lifetime ES2198409T3 (es) 1989-03-19 1990-03-15 Utilizacion del interferon-beta humano para la preparacion de composiciones farmaceuticas para el tratamiento de la leucemia mieloide cronica.

Country Status (12)

Country Link
US (1) US5104653A (es)
EP (2) EP0388799B1 (es)
JP (1) JP2883669B2 (es)
AT (2) ATE157544T1 (es)
AU (1) AU619960B2 (es)
CA (1) CA2011992C (es)
DE (2) DE69031355T2 (es)
DK (2) DK0643973T3 (es)
ES (2) ES2107414T3 (es)
GR (1) GR3024763T3 (es)
IL (1) IL89662A (es)
ZA (1) ZA901994B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
DE69636790T2 (de) * 1995-07-25 2007-10-11 Toray Industries, Inc. Interferon-beta gegen knochenerkrankungen
EP1053004A2 (en) 1998-02-09 2000-11-22 University Of Southern California Use of angiotensin analogues for promoting erythropoiesis
DE10020129C1 (de) * 2000-04-14 2001-11-15 Siemens Ag Baugruppe mit Überspannungsableiter für eine Hochspannungsanlage
AU3070702A (en) * 2000-11-07 2002-05-21 Chiron Corp Stabilized inteferon compositions
DE60108661T2 (de) * 2000-11-14 2006-01-05 Université Libre de Bruxelles Herstellung und verwendung von dendritischen zellen
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8084424B2 (en) * 2003-04-09 2011-12-27 University Of Utah Research Foundation Compositions and methods related to erythropoietin
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
AU2007217980A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
GB8412564D0 (en) * 1984-05-17 1984-06-20 Searle & Co Structure and properties
CA1294215C (en) * 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US4851219A (en) * 1986-11-18 1989-07-25 Genentech, Inc. Method for the treatment of chronic myelogenous leukemia
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders

Also Published As

Publication number Publication date
GR3024763T3 (en) 1997-12-31
ATE157544T1 (de) 1997-09-15
ATE240116T1 (de) 2003-05-15
IL89662A0 (en) 1989-09-28
DE69031355D1 (de) 1997-10-09
JP2883669B2 (ja) 1999-04-19
EP0643973B1 (en) 2003-05-14
AU5144590A (en) 1990-09-20
ES2198409T3 (es) 2004-02-01
DE69034076T2 (de) 2003-11-20
EP0388799A3 (en) 1991-07-31
ZA901994B (en) 1990-12-28
AU619960B2 (en) 1992-02-06
CA2011992C (en) 2003-04-29
EP0643973A1 (en) 1995-03-22
IL89662A (en) 1997-11-20
US5104653A (en) 1992-04-14
EP0388799B1 (en) 1997-09-03
CA2011992A1 (en) 1990-09-19
DK0388799T3 (da) 1998-03-30
DK0643973T3 (da) 2003-09-08
EP0388799A2 (en) 1990-09-26
DE69031355T2 (de) 1998-01-08
JPH0314523A (ja) 1991-01-23
DE69034076D1 (de) 2003-06-18

Similar Documents

Publication Publication Date Title
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
ES2107414T3 (es) Utilizacion de interferon-beta humano para la estimulacion de la eritropoyesis.
ES2069750T3 (es) Metodos y composiciones para curar huesos.
MX9304110A (es) Utilizacion de inhibidores del complemento para la preparacion de un medicamento destinado a la profilaxis y a la terapia de enfermedades intestinales y cutaneas inflamatorias asi como de purpura.
ES2147720T3 (es) Factor de celulas madre.
IT1224594B (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
ES2080837T3 (es) Tratamiento de estados y enfermedades.
ES2191192T3 (es) Tienopirimidinas.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
GR76810B (es)
ES290656Y (es) Dispositivo para recoger y mantener vivos los cultivos del cuerpo del paciente.
EP0151989A3 (en) Means for the treatment of cardiac diseases
ES2093607T3 (es) Rna bicatenario para la correccion de anomalias en complejos inmunes circulantes y en la funcion de los monocitos.
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
ATE111735T1 (de) Verwendung des wirkstoffs azelastin und glycerinethern zur bekämpfung von psoriasis- erkrankungen.
IT1183181B (it) Derivati del 3-metil-imidazo(4,5-c)pirazolo con attivita' terapeutica e procedimento per la loropreparazione
DE3850154D1 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
SE8400723L (sv) Farmaceutisk komposition
MX9203409A (es) Proteinas bcrfi como inhibidores de la gama interferona.
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
DE69001686D1 (de) Behandlung von leukozytstoerungen mit gm-csf.
ES2095984T3 (es) 2,3-dihidropirano(2,3-b)piridinas aminometil sustituidas, procedimiento para su preparacion y su uso en medicamentos.
ES2080954T3 (es) Uso de beta-aletina en cultivos de celulas y en terapia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 388799

Country of ref document: ES